An initial trial of an antibody therapy that targets Alzheimer's disease has shown promising results in treating the brain disorder.

Aducanumab is now being tested for efficacy in larger trials and if those are successful, the therapy could be the first ever Alzheimer's drug to reverse signs of the disease.

Scientists involved have hailed it as the best news in dementia research for 25 years and a potential game changer for people with the condition.

Waikato Hospital geriatrician, Dr Phil Wood, spoke with Mike Hosking about the therapy.